ClinicalTrials.gg
Enrolling by invitationNCT06847386Updated Feb 26, 2025

Effect of Hysteroscopic Metroplasty on Reproductive Outcome in Patients with RIF

An interventional study of Hysterocopic metroplasty in Recurrent Implantation Failure and T-Shaped Uterus, sponsored by Shanghai First Maternity and Infant Hospital. Enrolling by invitation at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-02-26.

Sponsored by Shanghai First Maternity and Infant Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 3 years 1 month after the study started (first participant enrolled Jan 2022, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Planned enrollment
21st of 51
200 · median 178
Started
2022
with 2 others
No phase
32 of 58
12 open now
Primary completion
2025-05
later than 2 of 19 live
Registered
49th of 58
by date

Among the 58 studies in Infertility, Female with a site in China, this one is the 21st largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2022, is one of 32 with no phase, reaches primary completion later than 2 of the 19 other live ones, and was the 49th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

In recent years with the continuous improvement of ART technology, it has brought new hope to infertile couples, however more than half of the patients still experience multiple transfer failures. Abnormalities in the structure of the uterine cavity are one of the main factors that lead to the failure of embryo implantation. Hysteroscopic metroplasty with cold scissors is an innovative technique of our team, in which micro-scissors are used in the procedure instead of the previous electric knife. Our previous study found that this technique has the effect of improving fertility outcomes in patients with T-shaped uterus.

Based on the previous study, this study is an open randomized controlled trial to include patients with more than 2 or more ART implantation failures. For the first time, cold knife hysteroscopic hysterectomy was used to treat patients with cryptic uterine stenosis in patients with repeated RIF implantation failures to assess the clinical efficacy of the technique and to investigate the effect of this technique on the pregnancy outcome of reimplantation of embryos in patients with repeated ART implantation failures. Meanwhile, this project is the first to study the diagnostic value of transvaginal 3D ultrasound/MRI for the assessment of uterine cavity status in patients with RIF, with a view to exploring the value of noninvasive imaging as an alternative to invasive hysteroscopy in the clinical management of RIF. The aim of the study is to provide a reference for early diagnosis and treatment of patients with repeated ART implantation failures, and to improve the pregnancy outcome of their reimplanted embryos.

03

Conditions studied

  • Recurrent Implantation Failure
  • T-Shaped Uterus

Browse trials for

Keywords

  • hysteroscopic metroplasty with cold scissiors
  • female infertility
  • recurrent implantation failure
  • reproductive outcome
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least twice previous implantation failures
  • Willing to receive further embryo transfer

Exclusion criteria

Exclusion Criteria:

  • Sturctural intrauterine lesions
  • Severe adenomyosis
  • Premature ovarian failure
  • > 35 kg/m\^2
  • Severe systemic disease or maligant tumor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Direct Embryo Transfer

    Patients in this group receive embryo transfer without hysteroscopy

  • Experimental
    Hysteroscopy

    Patients in this group receive hysteroscopic examination. If T-shaped uterus is diagnosed during the operation, hysteroscopic metroplasty will be performed.

    Procedure: Hysterocopic metroplasty

Interventions

  • ProcedureHysterocopic metroplasty

    If the uterine cavity is normal during intraoperative hysteroscopy, the operation will be finished and embryo transfer will be scheduled in 1 month after the operation; if the uterine cavity is narrowed or the uterine wall is coalesced, hysteroscopic metroplasty and IUD placement will be performed, and a second hysteroscopy with IUD retrieval will be performed after 2-month postoperative estrogen-progesterone treatment, then embryo transfer will be scheduled after 1-month estrogen-progesterone treatment.

06

What researchers measure

Primary outcomes

  1. Pregnancy rate

    Proportion of patients whose blood β-hCG test is positive after embryo transfer

    Time frame: From enrollment to the 18 months after the last embryo transfer

Secondary outcomes

  1. Biochemical pregnancy rate

    Proportion of patients who have elevated blood β-hCG (\> 25 mIU/mL) or positive urine immunopregnancy test, but ultrasound test reveal no gestational sac.

    Time frame: From enrollment to the 18 months after the last embryo transfer

  2. Clinical pregnancy rate

    Proportion of patients who have fetal primitive heart tube pulsation tested with ultrasonography 4 weeks after embryo transfer.

    Time frame: From enrollment to the 18 months after the last embryo transfer

  3. Fetal implantation rate

    Proportion of transfered embryos which develop into intrauterine gestational sacs.

    Time frame: From enrollment to the 18 months after the last embryo transfer

  4. Miscarriage rate

    Proportion of patients with unintentional termination of intrauterine pregnancy at 28 gestational weeks.

    Time frame: From enrollment to the 18 months after the last embryo transfer

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for May 2025, 40 months after the start.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 40 months is above that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Jan 1, 2022
Primary completionEst.
May 31, 2025
CompletionEst.
Jun 30, 2025
Last update
Feb 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847386
Lead sponsor
Shanghai First Maternity and Infant Hospital
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Jan 1, 2022
Primary completion
May 31, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Feb 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion